Sugi Predict

Sugi Predict / Compounds / SCHEMBL2659137

SCHEMBL2659137

SCHEMBL2659137

CC(C)(C(=O)OCc1ccccc1)P(=O)(O)O

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 5/20 0.55
▸ PTPRC P08575 2/20 0.55
▸ ALDH1A1 P00352 4/20 0.53
▸ TSHR P16473 1/20 0.49
▸ MAPK1 P28482 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ CETP P11597 3/20 0.45
▸ LMNA P02545 1/20 0.44
▸ HCAR2 Q8TDS4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28789807 0.84 PTPN1 (0.52) PTPN1PTPRCALDH1A1TSHRMAPK1
SCHEMBL5849989 0.81 PTPN1 (0.52) PTPN1PTPRCALDH1A1TSHRMAPK1
SCHEMBL19598833 0.81 PTPN1 (0.52) PTPN1PTPRCALDH1A1TSHRMAPK1
SCHEMBL991531 0.80 ALDH1A1 (0.62) PTPN1PTPRCALDH1A1TSHRMAPK1
SCHEMBL522510 0.80 ALDH1A1 (0.62) ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3
SCHEMBL24347012 0.79 ALDH1A1 (0.60) PTPN1PTPRCALDH1A1TSHRMAPK1
SCHEMBL1706652 0.79 ALDH1A1 (0.60) PTPN1PTPRCALDH1A1TSHRMAPK1
SCHEMBL3756497 0.79 ALDH1A1 (0.60) PTPN1PTPRCALDH1A1TSHRMAPK1
SCHEMBL28246707 0.79 ALDH1A1 (0.60) ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3
Ammonia Solution, Strong SCHEMBL27451848 0.79 ALDH1A1 (0.60) ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118515685-A Synthesis of halichondrin 哈佛大学的校长及成员们 2024-08-20 — — CN disclosed
CN-111433211-B Synthesis of halichondrin 哈佛大学的校长及成员们 2024-05-07 — — CN disclosed
US-20230128195-A1 SYNTHESIS OF HALICHONDRINS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-04-27 — — US disclosed
EP-4169924-A2 SYNTHESIS OF HALICHONDRINS President And Fellows Of Harvard College (US) 2023-04-26 — — EP disclosed
US-11548898-B2 Synthesis of halichondrins PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-01-10 — — US disclosed
EP-3649135-B1 SYNTHESIS OF HALICHONDRINS HARVARD COLLEGE (US) 2022-12-28 — — EP disclosed
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 — — US disclosed
US-20210230177-A1 SYNTHESIS OF HALICHONDRINS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-07-29 — — US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 — — US disclosed
EP-3511003-B1 CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF TORAY INDUSTRIES (JP) 2021-03-03 — — EP disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-8710236-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2014-04-29 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 — — EP disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed
US-7410984-B2 Compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-12 — — US disclosed
EP-0214639-B1 HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS G.D. Searle & Co. (US) 1990-06-13 — — EP disclosed
US-4743587-A ANTIARTHRITIC AGENTS G. D. SEARLE & CO. (US) 1988-05-10 — — US disclosed
EP-0214639-A2 Hydroxamic acid based collagenase inhibitors G.D. Searle & Co. (US) 1987-03-18 — — EP disclosed
US-4599361-A ANTIARTHRITIC G. D. SEARLE & CO. (US) 1986-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 PTPN1 663/4885PTPRC 1431/4885ALDH1A1 378/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 PTPN1 663/4885PTPRC 1431/4885ALDH1A1 378/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 PTPN1 489/4885PTPRC 1821/4885ALDH1A1 4642/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 PTPN1 489/4885PTPRC 1821/4885ALDH1A1 4642/4885
US-11548898-B2 Synthesis of halichondrins H1-3, NISCH, H1-5 PTPN1 4807/4885PTPRC 4206/4885ALDH1A1 1798/4885
US-20230128195-A1 SYNTHESIS OF HALICHONDRINS H1-3, NISCH, HDAC11 PTPN1 4809/4885PTPRC 4191/4885ALDH1A1 1842/4885
US-20210230177-A1 SYNTHESIS OF HALICHONDRINS H1-3, NISCH, HDAC11 PTPN1 4809/4885PTPRC 4171/4885ALDH1A1 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.